ABVC Key Statistics, Chart & Performance
The current stock price of ABVC is 2.11 USD. In the past month the price decreased by -24.64%. In the past year, price increased by 317.82%.
ABVC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About ABVC
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
Company Info
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA US
CEO: Howard Doong
Employees: 16
Phone: 15106680881
ABVC BIOPHARMA INC / ABVC FAQ
Can you describe the business of ABVC BIOPHARMA INC?
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. The company also focuses on the development of new drugs and medical devices derived from plants.
What is the current price of ABVC stock?
The current stock price of ABVC is 2.11 USD. The price decreased by -6.22% in the last trading session.
Does ABVC BIOPHARMA INC pay dividends?
ABVC does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABVC stock?
ABVC has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ABVC BIOPHARMA INC (ABVC) stock traded?
ABVC stock is listed on the Nasdaq exchange.
Can you provide the number of employees for ABVC BIOPHARMA INC?
ABVC BIOPHARMA INC (ABVC) currently has 16 employees.
Can you provide the market cap for ABVC BIOPHARMA INC?
ABVC BIOPHARMA INC (ABVC) has a market capitalization of 51.27M USD. This makes ABVC a Micro Cap stock.
ABVC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is one of the better performing stocks in the market, outperforming 98.35% of all stocks.
ABVC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVC. ABVC has a bad profitability rating. Also its financial health evaluation is rather negative.
ABVC Financial Highlights
Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 77.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.44% | ||
| ROE | -34.14% | ||
| Debt/Equity | 0.07 |